Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New pill shows promise for kidney disease in Mid-Stage trial

NCT ID NCT05016323

Disease control Sponsor: Jiangsu HengRui Medicine Co., Ltd. Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested a new drug called HR19042 in 316 adults with IgA nephropathy, a kidney disease. The goal was to see if the drug can reduce protein in the urine, a sign of kidney damage, and find the best dose. Participants took either the drug or a placebo for a set period, and researchers measured changes in kidney function and protein levels.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

316 people

The number who actually took part.

Started

Sep 2021

Finished

Aug 2025

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Female or male patients ≥18 years old； 2. Biopsy-confirmed primary IgA nephropathy； 3. Urine protein≥0.75 g/24hr or urine protein creatinine ratio (UPCR)≥0.5 g/g； 4. Estimated GFR (using the CKD-EPI2009 formula) ≥30mL/min/1.73 m2； 5. Willing and able to take adequate contraception during the trial; 6. Willing and able to give informed consent and follow the protocols during the trial. Exclusion Criteria: 1. Systemic diseases which could lead to secondary IgA nephropathy； 2. Patients with severe chronic infection or active infection under systemic antibiotic therapy in previous 14 days； 3. Patients with severe cardiovascular diseases； 4. Patients diagnosed with malignancy within the past 5 years； 5. Patients with liver cirrhosis； 6. Patients received organ transplantation； 7. Patients with uncontrolled Type 1 or 2 diabetes； 8. Positive results in HIV-Ab/TP-Ab/ HBsAg/HCV-Ab tests； 9. Patients treated with any systemic immunosuppressive drugs (excluding corticosteroids) within the past 12 months before screening； 10. Patients treated with any systemic corticosteroids within the past 3 months before screening.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for IgA nephropathy are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

IgA glomerulonephritis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

IgA nephropathy

Contacts and locations

Locations

  • NanFang Hospital of Southern Medical University

    Guangzhou, Guangdong, 510515, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.